PURPOSE 5 trial will evaluate lenacapavir as twice-yearly prevention option in people who could benefit from HIV PrEP in France and the United Kingdom
Gilead Sciences, Inc. announced PURPOSE 5, the first Phase 2 clinical trial to evaluate an investigational long-acting HIV prevention option in Europe. The study will assess the persistence—defined as consistent and continuous use—of lenacapavir compared with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in people who may benefit from pre-exposure prophylaxis (PrEP) and who are not currently taking PrEP. The study has an intentional focus on recruiting participants from groups across France and the United Kingdom that are disproportionally affected by HIV and often underrepresented in clinical trials.
Read the full press release here.
Source : Gilead Sciences, Inc.
Related HIV and Co-Infections News
-
[CROI 2026] HIV i-Base: Only three new HIV cases on lenacapavir PrEP: updates from PURPOSE-1 and -2
-
aidsmap: DoxyPEP halves overall syphilis cases, with possible indirect benefits for women
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.